Program funded by BARDA Contract number #75A50121C00059 V4.3-28AUG24
In the US, the FrontlineODPTM System is an investigational device not for sale, with clinical trials in progress.
Spray Dried Plasma System
We combine our passion, expertise, and transformative technology to stop preventable death by bleeding and save lives across the world.
Velico is a private, clinical stage medical technology company headquartered in Beverly, Massachusetts. We are committed to the mission of reducing preventable death from bleeding. We are developing a novel, spray dried plasma manufacturing system which will equip blood centers around the world to produce point of care, spray dried plasma products for transfusion. On Demand Plasma rehydrates in minutes making it suitable for early, pre-hospital use on ground and air ambulances, military settings and for mass casualty events.
MENU
Contents
Front Cover
Welcome
A Message from Richard
Introducing FrontlineODP™
Frontline System
Why is it needed?
Our Model
Contact Us
CLOSE
For over 20 years, Velico has been focused on developing innovative blood and plasma products for transfusion. We have focused our efforts on improving the usability, accessibility, and shelf life of specialized blood products. We have developed a broad portfolio of patents to protect our inventions. Our investment in talented people, intentional collaborations, innovative engineering and novel technology developments will yield products which will improve access to blood and save countless lives around the world upon release of our first product, FrontlineODP™. This, and the products that follow, will be vital to the future of blood.
President, CEO and Chairman
A message from Richard
Preventable death from hemorrhage following trauma is a global concern which has been targeted by surgeons, emergency medical providers, mass casualty planners, the military and national governments as a top priority. Velico is proud to be developing the FrontlineODP™ technology in support of this call to action. A FrontlineODP™ Unit is a spray dried plasma unit ready for rehydration. The intended use is to assist in the management of traumatic hemorrhage where conventional plasma is unavailable or impractical for use, such as pre-hospital transfusions, rural/ austere hospitals, or military applications.
This is our solution…
Liquid Plasma
VeliDryer
VeliSealer
FrontlineODPTM Unit
FrontlineODP™‘s spray dried plasma is designed for easy integration in blood center component laboratories. Decentralized production by blood centers aims to take advantage of deep blood component manufacturing expertise and product supply chains, from established volunteer blood donor bases to end user distribution including emergency logistics channels. Decentralized production sets the stage for local spray dried plasma self-sufficiency and national emergency preparedness including civilian, government and military collaboration for strategic stockpiles and readiness for major mass casualty events.
Stability Targets
Room Temperature 1 Year
FrontlineODPTM System
Produces spray dried plasma in the blood bank component lab Operates in a blood center environment Easy to integrate, operate and maintain
FrontlineODPTM (On Demand Plasma)
Comparable factor activity to traditional plasma products Has the potential to overcome storage and thawing logistics of frozen plasma Expected long shelf life Rehydrates in minutes at the point of care Decentralized manufacturing would ensure broad regional availability improving access for civilian/military hospital and prehospital use
Refrigerated 2 Years
Our production process:
30-40 percent of death from bleeding are considered preventable. Death from hemorrhage represents a substantial global problem, with more than 60,000 deaths per year in the United States and an estimated 1.9 million deaths per year worldwide, 1.5 million of which result from physical trauma†. A spray dried plasma solution promises increased access of blood product distribution throughout the EMT community. The longevity of spray dried plasma would enable emergency vehicles to carry this product for longer than whole blood or other alternatives without replenishing as often. In addition, as spray dried plasma is designed to be stored in ambient conditions, it has the potential to save more lives, especially where emergency vehicles may not have appropriate refrigerated facilities but could provide ambient controlled temperature storage conditions. † Cannon JW. Hemorrhagic shock. N Engl J Med. 2018 Jan 25;378(4):370-9
Velico’s model is based on partnerships with regional blood centers which collect, test and manufacture lifesaving blood components every day. Velico’s FrontlineODP™ system is designed for straight forward integration into existing blood centers.
Velico is developing a novel, platform technology for manufacturing spray dried human plasma. The FrontlineODP™ system is intended to be deployed at regional blood centers that will produce spray dried plasma for use by hospitals, emergency first responders and the military. Spray dried plasma overcomes the logistics of conventional plasma and potentially extends the availability of plasma from the hospital to the point of injury, including rural and austere settings. The resulting plasma units are compact and can be stored either refrigerated or at room temperature.
Resulting Plasma
FrontlineODPTM Model
Military Usage
Velico Medical Inc.
• Manufactures Systems / Consumables • Sells Systems / Consumables to Military Bases
Military Bases/ Local Blood Centers
• Produces FrontlineODPTM • Provides to Military Medical / Service Members
FrontlineODP™ is easily reconstituted with 200 ml of sterile water for injection (SWFI), and ready for use within minutes, making it practical in prehospital settings where conventional plasma is unavailable.
Rehydration
Uncontrolled hemorrhage is recognized as the leading cause of potentially preventable death among victims of trauma†. The early administration of plasma has been shown to be lifesaving for many of these patients. † Sperry JL, et al. Prehospital Plasma during Air Medical Transport in Trauma Patients at Risk for Hemorrhagic Shock. N Engl J Med. 2018 Jul 26;379(4):315-326
Transfusion
Ciaran Flanagan, Chief Marketing Officer
Together we can make a real difference
For more information please contact:
US: Europe:
R&D and Manufacturing 100 Cummings Center # 436H, Beverly, MA 01915, United States Sales, Distribution and Servicing 5 Clarendon Mews, Lad Lane, Dublin 2, Ireland, D02 EE61
www.veli.co
Velico’s development program has been funded in whole or in part with federal funds from the Department of Health and Human Services; Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority, under contract number 75A50121C00059.
US: +1 (781) 510 2257
EU: +353 (87) 245 6321
cflanagan@veli.co
+1 978 232 8370
+353 1 2500 055
Richard Meehan, President & CEO
US: +1 (978) 338 4590
EU: +353 (86) 020 9272
rmeehan@veli.co
